Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures

Schizophr Res. 1990 Oct-Dec;3(5-6):287-94. doi: 10.1016/0920-9964(90)90012-v.

Abstract

Neuropeptide Y-like immunoreactivity (NPY-li) was measured in CSF of 35 drug-free chronic schizophrenic patients. Compared to a group of drug-free controls, CSF NPY-li was significantly higher in these patients. CSF NPY-li decreased with age and longer duration of illness. Measures of structural brain abnormalities on CT scans were significantly associated with lower CSF NPY-li. Relationships between NPY-li and schizophrenic behavior, i.e. positive symptoms, were observed only in the clinically stable (nonrelapsed) drug-free patients. In 31 of the patients CSF was obtained before and after withdrawal from haloperidol maintenance treatment. This withdrawal from haloperidol treatment was associated with a significant increase in CSF NPY-li. There was no significant difference in CSF NPY-li between patients who did and those who did not relapse within 6 weeks following haloperidol withdrawal. The present findings suggest a relationship of CSF NPY-li with various aspects of schizophrenia.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Haloperidol / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Neuropeptide Y / cerebrospinal fluid*
  • Psychiatric Status Rating Scales
  • Receptors, Neuropeptide Y
  • Receptors, Neurotransmitter / drug effects
  • Receptors, Neurotransmitter / physiology
  • Recurrence
  • Schizophrenia / cerebrospinal fluid*
  • Schizophrenia / drug therapy
  • Schizophrenic Psychology*

Substances

  • Neuropeptide Y
  • Receptors, Neuropeptide Y
  • Receptors, Neurotransmitter
  • Haloperidol